Evidence map›Paper›PMID 27464262›Full record

ArticleAnnals of neurology2016

Long-term evolution of multiple sclerosis disability in the treatment era.

University of California, San Francisco MS-EPIC Team:, Bruce A C Cree, Pierre-Antoine Gourraud, Jorge R Oksenberg, Carolyn Bevan, Elizabeth Crabtree-Hartman, Jeffrey M Gelfand, Douglas S Goodin, Jennifer Graves, Ari J Green and 24 more

Open access · bronzeAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Annals of neurology, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 193 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
193citing papers in PubMed, 2 pooled it
33.4field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

193 citing papers in PubMed, 2 syntheses or guidelines pooled it, 433 citations in OpenAlex.

  1. Pooled it
  2. Dietary interventions for multiple sclerosis-related outcomes.The Cochrane database of systematic reviews · 2020
    Pooled it
  3. Trial
  4. Trial
  5. Trial
  6. Trial
  7. Trial
  8. Trial
  9. Trial
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Review
  17. Review
  18. Review
  19. Article
  20. Article

133 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

34 authors at 4 institutions in 1 country.

University of California, San Francisco MS-EPIC Team:
Bruce A C CreeDepartment of Neurology, University of California, San Francisco, San Francisco, CA. Bruce.Cree@ucsf.edu.
Pierre-Antoine GourraudDepartment of Neurology, University of California, San Francisco, San Francisco, CA.
Jorge R OksenbergDepartment of Neurology, University of California, San Francisco, San Francisco, CA.
Carolyn BevanDepartment of Neurology, University of California, San Francisco, San Francisco, CA.
Elizabeth Crabtree-HartmanDepartment of Neurology, University of California, San Francisco, San Francisco, CA.
Jeffrey M GelfandDepartment of Neurology, University of California, San Francisco, San Francisco, CA.
Douglas S GoodinDepartment of Neurology, University of California, San Francisco, San Francisco, CA.
Jennifer GravesDepartment of Neurology, University of California, San Francisco, San Francisco, CA.
Ari J GreenDepartment of Neurology, University of California, San Francisco, San Francisco, CA.
Ellen MowryDepartment of Neurology, University of California, San Francisco, San Francisco, CA.
Darin T OkudaDepartment of Neurology, University of Texas Southwestern Medical Center, Dallas, TX.
Daniel PelletierDepartment of Neurology, University of Southern California, Los Angeles, CA.
H-Christian von BüdingenDepartment of Neurology, University of California, San Francisco, San Francisco, CA.
Scott S ZamvilDepartment of Neurology, University of California, San Francisco, San Francisco, CA.
Alisha AgrawalDepartment of Neurology, University of California, San Francisco, San Francisco, CA.
Stacy CaillierDepartment of Neurology, University of California, San Francisco, San Francisco, CA.
Caroline CioccaDepartment of Neurology, University of California, San Francisco, San Francisco, CA.
Refujia GomezDepartment of Neurology, University of California, San Francisco, San Francisco, CA.
Rachel KannerDepartment of Neurology, University of California, San Francisco, San Francisco, CA.
Robin LincolnDepartment of Neurology, University of California, San Francisco, San Francisco, CA.
Antoine LizeeDepartment of Neurology, University of California, San Francisco, San Francisco, CA.
Pamela QualleyDepartment of Neurology, University of California, San Francisco, San Francisco, CA.
Adam SantanielloDepartment of Neurology, University of California, San Francisco, San Francisco, CA.
Leena SuleimanDepartment of Neurology, University of California, San Francisco, San Francisco, CA.
Monica BucciDepartment of Neurology, University of California, San Francisco, San Francisco, CA.
Valentina PanaraDepartment of Neurology, University of California, San Francisco, San Francisco, CA.
Nico PapinuttoDepartment of Neurology, University of California, San Francisco, San Francisco, CA.
William A SternDepartment of Neurology, University of California, San Francisco, San Francisco, CA.
Alyssa H ZhuDepartment of Neurology, University of California, San Francisco, San Francisco, CA.
Gary R CutterDepartment of Biostatistics, University of Alabama at Birmingham, Birmingham, AL.
Sergio BaranziniDepartment of Neurology, University of California, San Francisco, San Francisco, CA.
Roland G HenryDepartment of Neurology, University of California, San Francisco, San Francisco, CA.
Stephen L HauserDepartment of Neurology, University of California, San Francisco, San Francisco, CA.
University of California, San Francisco · USThe University of Texas Southwestern Medical Center · USUniversity of Alabama at Birmingham · USUniversity of Southern California · US

Funding

GENE LINKAGE STUDY OF MULTIPLE SCLEROSIS SIBLING PAIRSR01NS026799 · NINDS · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI HAUSER, STEPHEN L, OKSENBERG, JORGE R. · 1989 to 2018
$6.8M
Post GWAS approach to identify cell-specific genetic pathways underlying MS riskR01NS088155 · NINDS · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI BARANZINI, SERGIO E · 2014 to 2018
$2.2M
The effect of vitamin D on the clinical and imaging course of multiple sclerosisK23NS067055 · NINDS · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI MOWRY, ELLEN M. · 2010 to 2014
$881k
Correlating Multiple Sclerosis Phenotypes with GenotypesK23NS048869 · NINDS · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI CREE, BRUCE C · 2005 to 2009
$807k
NINDS NIH HHS K23 NS048869NINDS NIH HHS K23 NS067055NINDS NIH HHS R01 NS026799NINDS NIH HHS R01 NS088155
6 · The paper itself

Abstract

objectiveTo characterize the accrual of long-term disability in a cohort of actively treated multiple sclerosis (MS) patients and to assess whether clinical and magnetic resonance imaging (MRI) data used in clinical trials have long-term prognostic value.

methodsThis is a prospective study of 517 actively managed MS patients enrolled at a single center.

resultsMore than 91% of patients were retained, with data ascertained up to 10 years after the baseline visit. At this last assessment, neurologic disability as measured by the Expanded Disability Status Scale (EDSS) was stable or improved compared to baseline in 41% of patients. Subjects with no evidence of disease activity (NEDA) by clinical and MRI criteria during the first 2 years had long-term outcomes that were no different from those of the cohort as a whole. 25-OH vitamin D serum levels were inversely associated with short-term MS disease activity; however, these levels had no association with long-term disability. At a median time of 16.8 years after disease onset, 10.7% (95% confidence interval [CI] = 7.2-14%) of patients reached an EDSS ≥ 6, and 18.1% (95% CI = 13.5-22.5%) evolved from relapsing MS to secondary progressive MS (SPMS).

interpretationRates of worsening and evolution to SPMS were substantially lower when compared to earlier natural history studies. Notably, the NEDA 2-year endpoint was not a predictor of long-term stability. Finally, the data call into question the utility of annual MRI assessments as a treat-to-target approach for MS care. Ann Neurol 2016;80:499-510.

Indexed as

Disease ProgressionOutcome Assessment, Health CareSeverity of Illness IndexAdultFemaleFollow-Up StudiesHumansMaleMiddle AgedMultiple Sclerosis, Chronic ProgressiveMultiple Sclerosis, Relapsing-RemittingPersons with DisabilitiesPrognosis

Identifiers

PMID27464262
PMCPMC5105678
OpenAlexW2489432788

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.